DenovAI is developing foundational technology platforms that can design proteins de novo - completely from scratch. The company is starting the journey to design next generation therapeutics like high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters - all tailored to bind to their specific targets. Its AI-based platform for rapid de novo antibody discovery will design high-affinity binders to epitopes of choice, reduce the discovery process from months to days and broaden the scope of therapy to many more diseases. The platform for de novo protein design can design bespoke high-affinity binders for targets of choice – unlocking many applications in biologics and diagnostics.